Lymphocyte pharmacodynamics are not associated with autoimmunity or efficacy after alemtuzumab

OBJECTIVE: To examine the association between peripheral blood lymphocyte pharmacodynamics and autoimmune adverse events (AEs) or return of disease activity in alemtuzumab-treated patients with relapsing-remitting MS. METHODS: Patients received 2 alemtuzumab courses (12 mg/d IV; 5 days at baseline,...

Descripción completa

Detalles Bibliográficos
Autores principales: Wiendl, Heinz, Carraro, Matthew, Comi, Giancarlo, Izquierdo, Guillermo, Kim, Ho Jin, Sharrack, Basil, Tornatore, Carlo, Daizadeh, Nadia, Chung, Luke, Jacobs, Alan K., Hogan, Richard J., Wychowski, Linda V., Van Wijmeersch, Bart
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6865853/
https://www.ncbi.nlm.nih.gov/pubmed/31662412
http://dx.doi.org/10.1212/NXI.0000000000000635

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6865853/
https://www.ncbi.nlm.nih.gov/pubmed/31662412
http://dx.doi.org/10.1212/NXI.0000000000000635

Ejemplares similares